A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Trientine (Primary) ; Vemurafenib
- Indications Malignant melanoma
- Focus Adverse reactions
- 17 Nov 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 11 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 18 Mar 2014 New trial record